Good morning. Today’s deal news is a reminder to read past the headline number: what gets paid, by whom, and when?
DRI signs a US$316-million royalty deal
Toronto’s DRI Healthcare has signed agreements to buy royalty participation rights in U.S. net sales of tavapadon from funds managed by Bain Capital and NovaQuest. The US$316-million purchase price is payable at closing, which still depends on FDA approval and customary conditions, according to its September 21 announcement.
The package mixes sales royalties and milestones with four annual fixed payments of US$23.4 million on the first four anniversaries of FDA approval. Total receipts are capped at US$437.5 million. That cap is a ceiling, not a promised return. The interesting purchase here is a set of payment rights—not ownership of the drug company.
ALUULA splits the R&D bill
A much smaller number, with a different job to do. Victoria’s ALUULA reported on September 21 that it signed a milestone-staged funding agreement on September 17. IBERCISA will fund half of a C$730,000 research project; ALUULA funds the other half.
That makes IBERCISA’s share C$365,000—not C$730,000 of outside capital. ALUULA will work with UBC’s Composites Research Network on further optimization, testing and validation of materials for defence shelters and covers on land and at sea. This is an R&D funding commitment, not a report that the money has all arrived or that the work is finished.
Two quicker hits
Bullfrog sets a bigger target. The Vancouver explorer has upsized its proposed private placement to a maximum C$8 million: up to 40 million units at C$0.20 each. Closing is expected around September 29, subject to approvals, with net proceeds intended for its South Bullfrog project in Nevada and working capital. A bigger offering, yes; a completed raise, no.
Stamper shrinks the cheque and grows the share count. Its September 22 announcement describes a September 17 amendment to deferred payments for an acquisition completed in September 2025. Remaining cash falls from US$1.25 million to US$500,000, while shares rise from 8,561,644 to 16.5 million. Exchange acceptance and required approvals remain outstanding. Less cash, more equity: that changes the payment mix without proving a lower total economic price.
For information and education, not advice for a specific transaction or a prediction of value.
Make deal news part of your morning. Subscribe to Deal Flow Canada, and come back every weekday for fresh Canadian deal updates.